# Efficacy and Safety of Longidaza® for the Treatment of Patients With Residual Changes in the Lungs After COVID-19

> **NCT06383819** · PHASE3 · COMPLETED · sponsor: **NPO Petrovax** · enrollment: 392 (actual)

## Conditions studied

- Post-Acute COVID-19 Syndrome
- Lung Disease With Polymyositis
- Fibrosis
- Lung Diseases, Interstitial
- Lung; Disease, Interstitial, With Fibrosis

## Interventions

- **DRUG:** Longidaza®
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06383819
- **Lead sponsor:** NPO Petrovax
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-08
- **Primary completion:** 2023-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 392 (ACTUAL)
- **Last updated:** 2025-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06383819

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06383819, "Efficacy and Safety of Longidaza® for the Treatment of Patients With Residual Changes in the Lungs After COVID-19". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06383819. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*